Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Yuhan, Luoxin Deal Underscores Asian NSCLC Therapy Needs

Executive Summary

Yuhan and Luoxin's licensing agreement for a third generation EGFR inhibitor, the second such deal between South Korea and China, suggests robust demand for novel drugs for non-small cell lung cancer in Asia.

Advertisement

Related Content

Deal Watch: Sanofi Begins 2017 By Ending Vaccine JV, Completing Swap With Boehringer
Should Pharma Be Concerned About Cooling China-Korea Ties?
Korean Tagrisso Launch Builds On Extensive Local Data
Clovis Pulls Plug On Rociletinib On Expected FDA Rejection
Yuhan Joins Immuno-Oncology Wave Via Sorrento JV
Hanmi’s Roll Continues With ZAI China Cancer Deal

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

SC097017

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel